Semaglutide
Semaglutide scored 5.2 / 10 (⚖️ Neutral) on the BioHarmony scale as a Substance → Pharmaceutical / Drug. Once-weekly injectable GLP-1 receptor agonist.
What It Is
Once-weekly injectable GLP-1 receptor agonist. Transformative for obese T2D with cardiovascular disease. Context-dependent for metabolically healthy adults. Catastrophic risk floor triggered by NAION, gastroparesis, aspiration events.
Upside (4.22 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 4.8 | 1.200 | |
| Breadth of Benefits | 15% | 4.8 | 0.720 | |
| Evidence Quality | 25% | 4.5 | 1.125 | |
| Speed of Onset | 10% | 3.8 | 0.380 | |
| Durability | 10% | 1.5 | 0.150 | |
| Bioindividuality Upside | 15% | 4.3 | 0.645 | |
| Total | 4.220 |
Upside Rationale
Efficacy (4.8/5.0) — STEP 1 delivered −14.9% body weight at 68 weeks (placebo −2.4%); SELECT cut 3-point MACE by 20% (HR 0.80) in 17,604 non-diabetic adults; FLOW cut the kidney composite by 24% (HR 0.76) and stopped early for efficacy; SUSTAIN-6 cut MACE 26% in T2D. Cohen’s d for weight loss clears 0.8 (transformative). Four organ systems, four hard endpoints.
Breadth of benefits (4.8/5.0) — Weight, glycemia, cardiovascular mortality, kidney progression, MASH resolution (59% vs 17% placebo), blood pressure, lipids, hsCRP (−38%), and emerging signals in addiction (alcohol, nicotine, gambling) and possibly Alzheimer’s (EVOKE readout pending). Whole-body systemic.
Evidence quality (4.5/5.0) — 60+ completed Phase 3 RCTs, 100,000+ participants enrolled cumulatively, SELECT and FLOW both had independent academic steering committees. Cochrane rates semaglutide among the highest-efficacy GLP-1 RAs with moderate-to-high GRADE certainty. Cross-geography replication. −0.5 integrity adjustment for Novo-funded pivotals, but academic replication and hard-endpoint wins hold the ceiling.
Speed of onset (3.8/5.0) — Appetite suppression detectable within 1–2 weeks. Weight loss measurable by week 4, linear through ~60 weeks. HbA1c down 0.5% by week 12. CV curves separate around month 6.
Durability (1.5/5.0) — The single biggest weakness. STEP 4 withdrawal: switching to placebo at week 20 caused 6.9% regain; STEP 1 extension showed two-thirds of lost weight regained within one year off drug. Effectively a lifetime medication, not a cure.
Bioindividuality upside (4.3/5.0) — In STEP 1, 86% hit ≥5% weight loss, 69% hit ≥10%, 50% hit ≥15%, 32% hit ≥20%. Non-responder rate ~14%. Consistent across age, sex, BMI strata.
Downside (3.60 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 4.2 | 1.260 | |
| Side Effect Profile | 15% | 4.2 | 0.630 | |
| Financial Cost | 5% | 4.3 | 0.215 | |
| Time/Effort Burden | 5% | 1.5 | 0.075 | |
| Opportunity Cost | 5% | 3.0 | 0.150 | |
| Dependency / Withdrawal | 15% | 4.3 | 0.645 | |
| Reversibility | 25% | 2.5 | 0.625 | |
| Total | 3.600 | |||
| × 1.4 (risk asymmetry) | 5.040 |
Downside Rationale
Safety risk (4.2/5.0) — Catastrophic risk floor triggered. NAION HR 4.28 in T2D and 7.64 in obese adults (Hathaway, JAMA Ophthalmol 2024). Gastroparesis HR 9.09 (Sodhi, JAMA 2023), MDL 3094 tracking 3,500+ federal cases including permanent gastroparesis. Documented pulmonary aspiration deaths under anesthesia. Acute pancreatitis class signal. Thyroid C-cell tumor rodent signal under black box.
Side effect profile (4.2/5.0) — Nausea 40–75%, vomiting, diarrhea, constipation. Real-world discontinuation ~30–50% vs 4–7% in trials. Ozempic face, hair shedding, anhedonia, libido loss in patient forums. DEXA sub-studies show up to 45% of weight lost is lean mass.
Financial cost (4.3/5.0) — Wegovy $1,350/month cash US; Ozempic $1,000. Insurance spotty. Compounded $300–500/month with FDA-flagged risks.
Time/effort burden (1.5/5.0) — Weekly subcutaneous injection. Negligible effort.
Opportunity cost (3.0/5.0) — Blunts food reward, training appetite, social eating. Crowds out lifestyle and metabolic-flexibility work.
Dependency/withdrawal (4.3/5.0) — Two-thirds of lost weight regained within 12 months of stopping. Physiological set-point defense is fully intact. Chronic drug.
Reversibility (2.5/5.0) — Most users can stop and return to baseline (with weight regain). But NAION is permanent vision loss. Some gastroparesis persists post-discontinuation. Lean mass lost returns as fat mass, not muscle.
Verdict
✅ Best for: Adults with obesity and type 2 diabetes, established cardiovascular disease plus BMI ≥27, diabetic chronic kidney disease, or severe metabolic dysfunction who have genuinely tried lifestyle intervention. SELECT showed an 81% all-cause mortality HR. If you are heading toward a cardiovascular event, semaglutide is one of the most effective drugs ever invented.
❌ Avoid if: You are a metabolically healthy biohacker chasing longevity optimization; you have a history of MTC or MEN2; you have pancreatitis history, gastroparesis, diabetic retinopathy, or eating disorder history; you are pregnant or planning to be; you cannot commit to indefinite continuous use; you are unwilling to resistance train and eat 1.6+ g/kg protein to protect lean mass; or you are sourcing from gray-market compounders without GMP sterility assurance.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | New Score | Tier |
|---|---|---|
| Long-term oncology signal confirmed (Safety 4.2→5.0, Reversibility 2.5→3.5) | 4.6 / 10 | ⚠️ Proceed with caution |
| Lean-mass-sparing co-agent approved (Side effects 4.2→3.0, Dependency 4.3→3.5) | 5.5 / 10 | ⚖️ Neutral |
| EVOKE Alzheimer’s positive (Breadth 4.8→5.0, Evidence 4.5→4.7) | 5.2 / 10 | ⚖️ Neutral |
| NAION incidence revises upward (Safety 4.2→4.8) | 4.9 / 10 | ⚖️ Neutral |
Key Evidence Sources
- Wilding JPH et al. STEP 1. NEJM 2021 — PMID 33567185
- Lincoff AM et al. SELECT. NEJM 2023 — PMID 37952131
- Perkovic V et al. FLOW. NEJM 2024 — PMID 38785209
- Marso SP et al. SUSTAIN-6. NEJM 2016 — PMID 27633186
- Rubino D et al. STEP 4 withdrawal. JAMA 2021 — PMID 33755728
- Hathaway JT et al. NAION risk. JAMA Ophthalmol 2024 — PMID 38985475
- Newsome PN et al. Semaglutide in NASH. NEJM 2021 — PMID 33185364
- Shi Q et al. Network meta-analysis. BMJ 2024 — PMID 38286487
- Ryan DH et al. SELECT CV benefit. Nat Med 2024 — PMID 38740993
- FDA Wegovy prescribing information — Wegovy PI
Other interventions for Cardiovascular
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. 5.0 is neutral (benefits and risks balance). Above 5 = benefits outweigh risks; below 5 = risks outweigh benefits. Every downside dimension is multiplied by 1.4 before subtraction because harm potential is more consequential than benefit potential — the precautionary principle encoded as math.
Upside: 4.220 / 5.00
Downside (post-1.4×): 3.600 / 5.00
EV = 0.620
Score = ((EV + 7) / 12) × 10 = 5.2 / 10
